Key Developments: Aspen Technology Inc (AZPN.O)
Latest Key Developments (Source: Significant Developments)
Final Judgment and Permanent Injunction Entered Against M3 Technology in Favor of Aspen Technology, Inc.
Aspen Technology, Inc. announced that a final judgment and permanent injunction was entered on June 6, 2012, in favor of AspenTech in its trade secret misappropriation, copyright infringement and tortious interference action against M3 Technology, Inc. in the United States District Court for the Southern District of Texas. The permanent injunction prohibits M3 Technology from using, marketing, selling, distributing, licensing, modifying, servicing, copying, or offering for sale or license the following products: SIMTO Scheduling/M-Blend/Global (versions 6.0, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 7.0, 7.1, 7.2, 8.0); SIMTO Scheduling/M-Blend (versions 3.6, 4.0, 4.5, 4.6, 4.8, 4.9, 5.0); SIMTO Scheduling (versions 1.0, 2.0, 2.3, 3.0); and SIMTO Distribution In addition, M3 Technology was ordered to pay Aspen Technology the sum of $11,346,329 in damages. Full Article
Aspen Technology, Inc. Raises FY 2012 Guidance; Issues Q4 2012 Guidance In Line With Analysts' Estimates-Conference Call
Aspen Technology, Inc. announced raising its fiscal 2012 revenue guidance to approximately $240 million to $242 million, which is above its prior guidance of $235 million to $240 million. GAAP operating loss is approximately $18.5 million to $20.5 million, which is an improvement from its prior guidance of an operating loss of $23 million to $33 million. The Company's updated forecast is for a GAAP net loss of approximately $14.5 million to $16.5 million, or a loss of $0.16 to $0.18 per share, which is an improvement from its prior guidance of a loss of $0.21 to $0.32. From a non-GAAP perspective, the Company is now targeting a non-GAAP operating loss (EBIT) of approximately $6 million to $8 million, which is an improvement compared to its prior guidance of a non-GAAP operating loss of $13 million to $23 million. The Company now expect a non-GAAP loss per share (EPS) of $0.06 to $0.08. For the fourth quarter of 2012, the Company expects revenue of approximately $61 million to $63 million, GAAP operating loss in a range of $7 million to $9 million and non-GAAP operating loss of approximately $4 million to $6 million. According to I/BE/S Estimates, analysts on an average were expecting the Company to report revenue of $239 million, EBIT of $(19) million and EPS of $(0.13) for fiscal 2012; and revenue of $63 million and EBIT of $(5) million for the fourth quarter of 2012. Full Article
JOHANNESBURG, March 6 - South African generic drug maker Aspen Pharmacare reported a 23 percent increase in first-half profit on Thursday, boosted by robust performance from its overseas business.